GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Financial Strength

CPMD (Cannapharmarx) Financial Strength : 0 (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Financial Strength?

Cannapharmarx has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Cannapharmarx did not have earnings to cover the interest expense. Cannapharmarx's debt to revenue ratio for the quarter that ended in Dec. 2024 was 7.29. As of today, Cannapharmarx's Altman Z-Score is -18.01.


Competitive Comparison of Cannapharmarx's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannapharmarx's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Financial Strength distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's Financial Strength falls into.


;
;

Cannapharmarx Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Cannapharmarx's Interest Expense for the months ended in Dec. 2024 was $-0.32 Mil. Its Operating Income for the months ended in Dec. 2024 was $-1.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $4.89 Mil.

Cannapharmarx's Interest Coverage for the quarter that ended in Dec. 2024 is

Cannapharmarx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Cannapharmarx's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9.168 + 4.893) / 1.928
=7.29

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Cannapharmarx has a Z-score of -18.01, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -18.01 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannapharmarx  (OTCPK:CPMD) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Cannapharmarx has the Financial Strength Rank of 0.


Cannapharmarx Financial Strength Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannapharmarx Business Description

Traded in Other Exchanges
N/A
Address
3204-Rideau Place SW, Suite 302, Calgary, AB, CAN, T2S 1Z2
Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. Its products Unique Genetics, Craft Products, and Medical Cannabis.
Executives
Anthony Michael Panek director 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin director, officer: Chief Executive Officer C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels officer: Chief Financial Officer SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman director 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman officer: Chief Operating Officer 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson director 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick 10 percent owner 7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson director PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia director, 10 percent owner 2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess director 2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood director P.O. BOX 4375, DILLON CO 80435
James E Smeeding director 4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife director 9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule director C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920